Overview

The Effect of Ixazomib on the Latent HIV Reservoir

Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine the safety and tolerability of Ixazomib in HIV infected patients who are on a stable regimen of ART that suppresses HIV replication. A secondary goal is to determine the effect of ixazomib on the size of the HIV reservoir.
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic
Nathan W. Cummins, M.D.
Collaborator:
Takeda
Treatments:
Glycine
Ixazomib